Data gathered: March 6
Alternative Data for Evolus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 23 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 39,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 41 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| App Downloads | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 12 | Sign up | Sign up | Sign up |
| Facebook Followers | 7,509 | Sign up | Sign up | Sign up |
| Instagram Followers | 52,519 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,853 | Sign up | Sign up | Sign up |
| Twitter Followers | 692 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 63 | Sign up | Sign up | Sign up |
| Linkedin Employees | 381 | Sign up | Sign up | Sign up |
About Evolus
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
| Price | $14.17 |
| Target Price | Sign up |
| Volume | 809,750 |
| Market Cap | $909M |
| Year Range | $9.47 - $17.49 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 GuidanceMarch 4 - Finnhub |
|
 |
Evolus, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 4 - SeekingAlpha |
|
Evolus, Inc. (EOLS) Q4 2024 Earnings Call TranscriptMarch 4 - SeekingAlpha |
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 GuidanceMarch 4 - Finnhub |
|
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor ConferencesFebruary 26 - Finnhub |
|
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness SummitFebruary 19 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 61M | 72M | -10M | -19M | -15M | -0.160 |
| Q2 '24 | 67M | 70M | -3.5M | -11M | -6.5M | -0.040 |
| Q1 '24 | 55M | 64M | -9.7M | -13M | -7.2M | -0.090 |
| Q4 '23 | 57M | 63M | -6.5M | -12M | -6.6M | -0.120 |
| Q3 '23 | 46M | 60M | -14M | -17M | -12M | -0.160 |
Insider Transactions View All
| Beaver Sandra filed to sell 146,916 shares at $10.9. December 26 '24 |
| Avelar Rui filed to sell 366,595 shares at $10.9. December 26 '24 |
| MOATAZEDI DAVID filed to sell 522,847 shares at $10.9. December 26 '24 |
| Beaver Sandra filed to sell 148,502 shares at $15. September 6 '24 |
| Yamagishi-Dressler Tomoko filed to sell 82,375 shares at $15.9. September 4 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$165.12 0% | 45 |
 |
Eli Lilly and CompanyLLY |
$929.72 0% | 54 |
 |
PfizerPFE |
$25.94 0% | 48 |
 |
AstrazenecaAZN |
$77.96 0% | 44 |
 |
AbbVieABBV |
$211.54 0% | 45 |
Read more about Evolus (EOLS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, app downloads, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Evolus?
The Market Cap of Evolus is $909M.
What is the current stock price of Evolus?
Currently, the price of one share of Evolus stock is $14.17.
How can I analyze the EOLS stock price chart for investment decisions?
The EOLS stock price chart above provides a comprehensive visual representation of Evolus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Evolus shares. Our platform offers an up-to-date EOLS stock price chart, along with technical data analysis and alternative data insights.
Does EOLS offer dividends to its shareholders?
As of our latest update, Evolus (EOLS) does not offer dividends to its shareholders. Investors interested in Evolus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Evolus?
Some of the similar stocks of Evolus are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.